ReViral raises $55 million to advance RSV clinical studies

1 August 2018

UK-based antiviral drug discovery and development company ReViral today announced the successful completion of a $55 million Series B financing.

The financing was led by New Leaf Venture Partners and Novo Ventures, part of Novo Holdings A/S, with additional new investment from Perceptive Advisors. Existing investors Andera Partners, OrbiMed and Brace Pharma Capital also participated in the fundraising.

The new funding will enable ReViral to progress its lead drug candidate (RV521), a highly potent and orally bioavailable potential treatment for respiratory syncytial virus (RSV) infections, into Phase IIa pediatric and adult trials, and to continue the development of a novel series of antiviral inhibitors targeting RSV replication. RV521 is soon expected to enter an international multicenter Phase IIa pediatric trial. This study will be followed by additional trials in adult stem cell transplant patients, the British biotech firm said.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK